デフォルト表紙
市場調査レポート
商品コード
1427064

全身性強皮症治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測(2031年)- 標的臓器別、治療タイプ別、投与経路別、流通チャネル別、地域別

Systemic Scleroderma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

出版日: | 発行: Fairfield Market Research | ページ情報: 英文 380 Pages | 納期: 2~5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.74円
全身性強皮症治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測(2031年)- 標的臓器別、治療タイプ別、投与経路別、流通チャネル別、地域別
出版日: 2024年02月01日
発行: Fairfield Market Research
ページ情報: 英文 380 Pages
納期: 2~5営業日
  • 全表示
  • 概要
  • 目次
概要

世界の全身性強皮症治療の市場規模は、予測期間の2024年~2031年にかけて大幅な成長を遂げるとみられています。同市場は現在8億5,000万米ドルとなっており、2031年末までに16億5,000万米ドルに急増すると予測されています。この成長軌道は、全身性強皮症に対する効果的な治療オプションに対する需要が世界中で高まっていることを裏付けています。

全身性強皮症治療市場を促進する主な要因の一つは、予防ヘルスケアへの取り組みに対する意識の高まりです。全身性強皮症のような自己免疫疾患に焦点を当てた啓発プログラムやワークショップは、疾患の適応に対する反応性の向上に寄与しています。さらに、生物学的製剤や低分子併用療法などの革新的な治療法の開発が、この分野の製薬メーカーに大きなチャンスをもたらしています。

カンナビジオール(CBD)由来の経口製剤であるEmerald Health PharmaceuticalsのEHP-101は、全身性強皮症を対象に現在第II相試験を実施中であり、この分野の企業が追求している革新的アプローチの一例に過ぎません。

有望な展望にもかかわらず、全身性強皮症治療には課題が残されています。治療法を評価するための標準化された枠組みの欠如と、疾患修飾性抗うつ薬の有効性が証明されていないことが、需要の伸びを阻害しています。臨床試験は、本疾患の低い有病率、多様な臨床症状、変動する経過のため、一貫性のない結果につながるというハードルに直面しています。

当レポートでは、世界の全身性強皮症治療市場について調査し、市場の概要とともに、標的臓器別、治療タイプ別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の全身性強皮症治療市場の見通し、2018年~2031年

  • 世界の全身性強皮症治療市場の見通し、標的臓器別、金額(100万米ドル)、2018年~2031年
  • 世界の全身性強皮症治療市場の見通し、治療タイプ別、金額(100万米ドル)、2018年~2031年
  • 世界の全身性強皮症治療市場の見通し、投与経路別、金額(100万米ドル)、2018年~2031年
  • 世界の全身性強皮症治療市場の見通し、流通チャネル別、金額(100万米ドル)、2018年~2031年
  • 世界の全身性強皮症治療市場の見通し、地域別、金額(100万米ドル)、2018年~2031年

第4章 北米の全身性強皮症治療市場の見通し、2018年~2031年

第5章 欧州の全身性強皮症治療市場の見通し、2018年~2031年

第6章 アジア太平洋の全身性強皮症治療市場の見通し、2018年~2031年

第7章 ラテンアメリカの全身性強皮症治療市場の見通し、2018年~2031年

第8章 中東・アフリカの全身性強皮症治療市場の見通し、2018年~2031年

第9章 競合情勢

  • 標的臓器と投与経路のヒートマップ
  • メーカーと適応症のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競合ダッシュボード
  • 企業プロファイル
    • Pfizer Inc.
    • Novartis AG
    • GlaxoSmithKline plc.
    • Sanofi SA
    • Lupin Ltd
    • Cipla Ltd
    • Johnson & Johnson Services Inc.
    • Bayer Healthcare LLC
    • F. Hoffmann-La Roche Ltd
    • Amgen Inc
    • Zydus Lifesciences Ltd
    • Casper Pharma
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Organon LLC
    • Accord Healthcare Inc.

第10章 付録

目次

Comprehensive Industry Analysis Reveals Robust Growth Opportunities

The global systemic scleroderma treatment market is witnessing substantial growth over the forecast period 2024-2031. According to Fairfield Market Research, the market is currently valued at US$ 850 million, and is anticipated to surge to a valuation of US$ 1650 million by the end of 2031. This growth trajectory underscores the increasing demand for effective treatment options for systemic scleroderma worldwide.

Increasing Awareness and Strong Product Pipeline Driving Market Growth

One of the key drivers propelling the systemic scleroderma treatment market is the rising awareness about preventive healthcare initiatives. Awareness programs and workshops focusing on autoimmune disorders like systemic scleroderma are contributing to greater responsiveness towards disease indications. Additionally, the development of innovative therapies such as biologics and small molecule combination therapies is opening up significant opportunities for drug manufacturers in this space.

Emerald Health Pharmaceuticals' EHP-101, an oral formulation derived from cannabidiol (CBD), is currently in phase II trials for systemic scleroderma, representing just one example of the innovative approaches being pursued by companies in the field.

Challenges Hindering Market Growth

Despite the promising outlook, challenges remain in the systemic scleroderma treatment landscape. A lack of standardized frameworks for assessing treatments and the absence of proven efficacy in disease-modifying anti-drugs are impeding demand growth. Clinical trials face hurdles due to the disease's low prevalence, diverse clinical manifestations, and fluctuating course, leading to inconsistent outcomes.

Country-wise Insights Highlight Regional Dynamics

  • United States: With the highest prevalence of systemic scleroderma, the U.S. accounts for a significant share of the North American market. Increasing focus on the treatment of rare diseases and USFDA approvals for systemic scleroderma drugs are driving market growth in this region.
  • Germany: Favorable guidelines for systemic scleroderma treatment in Germany are facilitating steady market growth, with researchers leveraging diagnostic scores and clinical features to advance therapy approaches.
  • Japan: Ongoing R&D efforts in Japan, highlighted by companies like Kyowa Kirin and J&J, are propelling the country's emergence as a prominent market for systemic scleroderma treatment.
  • Australia: High prevalence rates and increasing mortality underscore the growing demand for systemic scleroderma treatments in Australia, driven by biomedical research discoveries and the introduction of new medical products.

Category-wise Insights Drive Market Understanding

  • Drug Therapy Segment: Off-label use of drugs approved for symptomatic indications is a key driver of market growth, with drug therapy expected to dominate the systemic scleroderma treatment market.
  • Route of Administration: Injectable drugs are preferred for their safety and efficacy, comprising the majority of systemic scleroderma treatment options.
  • Sales Channels: Hospital pharmacies dominate sales due to the need for skilled medical administration, with intravenous drug administration being common for systemic scleroderma treatments.

Impact of COVID-19

While the COVID-19 pandemic disrupted healthcare supply chains, studies have shown a neutral impact on the systemic scleroderma treatment market. However, patients with systemic scleroderma-related interstitial lung involvement faced higher risks of severe COVID-19, highlighting the importance of continued research and treatment development.

Competitive Analysis

Key players in the systemic scleroderma treatment market are forging strategic partnerships and acquisitions to expand their product portfolios and drive innovation. Recent partnerships include Boehringer Ingelheim with PetMedix and Lupin ltd with Shenzhen Foncoo Pharmaceutical Co. Ltd, underscoring the industry's commitment to advancing treatment options.

As the market continues to evolve, collaborations and investments in R&D will play a crucial role in addressing the unmet needs of systemic scleroderma patients worldwide.

Key Companies Profiled:

  • Pfizer Inc.
  • Novartis AG
  • GlaxoSmithKline plc.
  • Sanofi SA
  • Lupin Ltd
  • Cipla Ltd
  • Teva Pharmaceuticals
  • Johnson & Johnson Services Inc.
  • Bayer Healthcare LLC
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc
  • Zydus Lifesciences Ltd
  • Casper Pharma
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Organon LLC
  • Accord Healthcare Inc.

Key Segments Covered in Systemic Scleroderma Treatment Industry Survey

Systemic Scleroderma Treatment Market by Target Organ:

  • Skin Fibrosis
  • Musculoskeletal
  • Digital Ulcers
  • Pulmonary Arterial Hypertension
  • Gastrointestinal
  • Pulmonary Fibrosis
  • Scleroderma Renal Crisis

Systemic Scleroderma Treatment Market by Treatment Type:

  • Drug Therapy
    • Corticosteroids
    • Immunosuppressants
    • Nonsteroidal Anti-Inflammatory Drugs
    • Calcium Channel Blockers
    • Proton Pump Inhibitors
    • TNF Inhibitors
    • Endothelin Receptor Antagonists
    • Phosphodiesterase Type 5 Inhibitors
    • Angiotensin-Converting Enzyme
  • Hematopoietic Stem Cell Transplantation (HSCT)

Systemic Scleroderma Treatment Market by Route of Administration:

  • Injectable Systemic Scleroderma Drugs
  • Oral Systemic Scleroderma Drugs
  • Topical Systemic Scleroderma Drugs

Systemic Scleroderma Treatment Market by Distribution Channel:

  • Hospital Pharmacies
  • Speciality Clinics
  • Retail Pharmacies
  • Online Pharmacies

Systemic Scleroderma Treatment Market by Region:

  • North America Systemic Scleroderma Treatment Market
  • Latin America Systemic Scleroderma Treatment Market
  • Europe Systemic Scleroderma Treatment Market
  • South Asia Systemic Scleroderma Treatment Market
  • East Asia Systemic Scleroderma Treatment Market
  • Oceania Systemic Scleroderma Treatment Market
  • The Middle East & Africa Systemic Scleroderma Treatment Market

Table of Contents

1. Executive Summary

  • 1.1. Global Systemic Scleroderma Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Skin Fibrosis
      • 3.1.1.2. Musculoskeletal
      • 3.1.1.3. Digital Ulcers
      • 3.1.1.4. Pulmonary Arterial Hypertension
      • 3.1.1.5. Gastrointestinal
      • 3.1.1.6. Pulmonary Fibrosis
      • 3.1.1.7. Scleroderma Renal Crisis
  • 3.2. Global Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Drug Therapy
        • 3.2.1.1.1. Corticosteroids
        • 3.2.1.1.2. Immunosuppressants
        • 3.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 3.2.1.1.4. Calcium Channel Blockers
        • 3.2.1.1.5. Proton Pump Inhibitors
        • 3.2.1.1.6. TNF Inhibitors
        • 3.2.1.1.7. Endothelin Receptor Antagonists
        • 3.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 3.2.1.1.9. Angiotensin-Converting Enzyme
      • 3.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 3.3. Global Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Injectable Systemic Scleroderma Drugs
      • 3.3.1.2. Oral Systemic Scleroderma Drugs
      • 3.3.1.3. Topical Systemic Scleroderma Drugs
  • 3.4. Global Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospital Pharmacies
      • 3.4.1.2. Speciality Clinics
      • 3.4.1.3. Retail Pharmacies
      • 3.4.1.4. Online Pharmacies
  • 3.5. Global Systemic Scleroderma Treatment Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Skin Fibrosis
      • 4.1.1.2. Musculoskeletal
      • 4.1.1.3. Digital Ulcers
      • 4.1.1.4. Pulmonary Arterial Hypertension
      • 4.1.1.5. Gastrointestinal
      • 4.1.1.6. Pulmonary Fibrosis
      • 4.1.1.7. Scleroderma Renal Crisis
  • 4.2. North America Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Drug Therapy
        • 4.2.1.1.1. Corticosteroids
        • 4.2.1.1.2. Immunosuppressants
        • 4.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 4.2.1.1.4. Calcium Channel Blockers
        • 4.2.1.1.5. Proton Pump Inhibitors
        • 4.2.1.1.6. TNF Inhibitors
        • 4.2.1.1.7. Endothelin Receptor Antagonists
        • 4.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 4.2.1.1.9. Angiotensin-Converting Enzyme
      • 4.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 4.3. North America Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Injectable Systemic Scleroderma Drugs
      • 4.3.1.2. Oral Systemic Scleroderma Drugs
      • 4.3.1.3. Topical Systemic Scleroderma Drugs
  • 4.4. North America Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies
      • 4.4.1.2. Speciality Clinics
      • 4.4.1.3. Retail Pharmacies
      • 4.4.1.4. Online Pharmacies
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Systemic Scleroderma Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 4.5.1.2. U.S. Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 4.5.1.3. U.S. Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 4.5.1.4. U.S. Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 4.5.1.5. Canada Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 4.5.1.6. Canada Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 4.5.1.7. Canada Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 4.5.1.8. Canada Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Skin Fibrosis
      • 5.1.1.2. Musculoskeletal
      • 5.1.1.3. Digital Ulcers
      • 5.1.1.4. Pulmonary Arterial Hypertension
      • 5.1.1.5. Gastrointestinal
      • 5.1.1.6. Pulmonary Fibrosis
      • 5.1.1.7. Scleroderma Renal Crisis
  • 5.2. Europe Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Drug Therapy
        • 5.2.1.1.1. Corticosteroids
        • 5.2.1.1.2. Immunosuppressants
        • 5.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 5.2.1.1.4. Calcium Channel Blockers
        • 5.2.1.1.5. Proton Pump Inhibitors
        • 5.2.1.1.6. TNF Inhibitors
        • 5.2.1.1.7. Endothelin Receptor Antagonists
        • 5.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 5.2.1.1.9. Angiotensin-Converting Enzyme
      • 5.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 5.3. Europe Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Injectable Systemic Scleroderma Drugs
      • 5.3.1.2. Oral Systemic Scleroderma Drugs
      • 5.3.1.3. Topical Systemic Scleroderma Drugs
  • 5.4. Europe Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Speciality Clinics
      • 5.4.1.3. Retail Pharmacies
      • 5.4.1.4. Online Pharmacies
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Systemic Scleroderma Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.2. Germany Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.3. Germany Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.4. Germany Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.5. U.K. Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.6. U.K. Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.7. U.K. Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.8. U.K. Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.9. France Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.10. France Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.11. France Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.12. France Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.13. Italy Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.14. Italy Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.15. Italy Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.16. Italy Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.17. Turkey Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.18. Turkey Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.19. Turkey Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.20. Turkey Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.21. Russia Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.22. Russia Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.23. Russia Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.24. Russia Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Skin Fibrosis
      • 6.1.1.2. Musculoskeletal
      • 6.1.1.3. Digital Ulcers
      • 6.1.1.4. Pulmonary Arterial Hypertension
      • 6.1.1.5. Gastrointestinal
      • 6.1.1.6. Pulmonary Fibrosis
      • 6.1.1.7. Scleroderma Renal Crisis
  • 6.2. Asia Pacific Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Drug Therapy
        • 6.2.1.1.1. Corticosteroids
        • 6.2.1.1.2. Immunosuppressants
        • 6.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 6.2.1.1.4. Calcium Channel Blockers
        • 6.2.1.1.5. Proton Pump Inhibitors
        • 6.2.1.1.6. TNF Inhibitors
        • 6.2.1.1.7. Endothelin Receptor Antagonists
        • 6.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 6.2.1.1.9. Angiotensin-Converting Enzyme
      • 6.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 6.3. Asia Pacific Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Injectable Systemic Scleroderma Drugs
      • 6.3.1.2. Oral Systemic Scleroderma Drugs
      • 6.3.1.3. Topical Systemic Scleroderma Drugs
  • 6.4. Asia Pacific Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Speciality Clinics
      • 6.4.1.3. Retail Pharmacies
      • 6.4.1.4. Online Pharmacies
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia Pacific Systemic Scleroderma Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.2. China Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.3. China Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.4. China Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.5. Japan Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.6. Japan Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.7. Japan Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.8. Japan Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.9. South Korea Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.10. South Korea Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.11. South Korea Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.12. South Korea Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.13. India Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.14. India Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.15. India Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.16. India Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Skin Fibrosis
      • 7.1.1.2. Musculoskeletal
      • 7.1.1.3. Digital Ulcers
      • 7.1.1.4. Pulmonary Arterial Hypertension
      • 7.1.1.5. Gastrointestinal
      • 7.1.1.6. Pulmonary Fibrosis
      • 7.1.1.7. Scleroderma Renal Crisis
  • 7.2. Latin America Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Drug Therapy
        • 7.2.1.1.1. Corticosteroids
        • 7.2.1.1.2. Immunosuppressants
        • 7.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 7.2.1.1.4. Calcium Channel Blockers
        • 7.2.1.1.5. Proton Pump Inhibitors
        • 7.2.1.1.6. TNF Inhibitors
        • 7.2.1.1.7. Endothelin Receptor Antagonists
        • 7.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 7.2.1.1.9. Angiotensin-Converting Enzyme
      • 7.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 7.3. Latin America Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Injectable Systemic Scleroderma Drugs
      • 7.3.1.2. Oral Systemic Scleroderma Drugs
      • 7.3.1.3. Topical Systemic Scleroderma Drugs
  • 7.4. Latin America Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Speciality Clinics
      • 7.4.1.3. Retail Pharmacies
      • 7.4.1.4. Online Pharmacies
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Systemic Scleroderma Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 7.5.1.2. Brazil Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.3. Brazil Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.4. Brazil Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.5.1.5. Mexico Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 7.5.1.6. Mexico Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.7. Mexico Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.8. Mexico Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.5.1.9. Argentina Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 7.5.1.10. Argentina Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.11. Argentina Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.12. Argentina Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, by Target Organ, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Skin Fibrosis
      • 8.1.1.2. Musculoskeletal
      • 8.1.1.3. Digital Ulcers
      • 8.1.1.4. Pulmonary Arterial Hypertension
      • 8.1.1.5. Gastrointestinal
      • 8.1.1.6. Pulmonary Fibrosis
      • 8.1.1.7. Scleroderma Renal Crisis
  • 8.2. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Drug Therapy
        • 8.2.1.1.1. Corticosteroids
        • 8.2.1.1.2. Immunosuppressants
        • 8.2.1.1.3. Nonsteroidal Anti-Inflammatory Drugs
        • 8.2.1.1.4. Calcium Channel Blockers
        • 8.2.1.1.5. Proton Pump Inhibitors
        • 8.2.1.1.6. TNF Inhibitors
        • 8.2.1.1.7. Endothelin Receptor Antagonists
        • 8.2.1.1.8. Phosphodiesterase Type 5 Inhibitors
        • 8.2.1.1.9. Angiotensin-Converting Enzyme
      • 8.2.1.2. Hematopoietic Stem Cell Transplantation (HSCT)
  • 8.3. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Injectable Systemic Scleroderma Drugs
      • 8.3.1.2. Oral Systemic Scleroderma Drugs
      • 8.3.1.3. Topical Systemic Scleroderma Drugs
  • 8.4. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Speciality Clinics
      • 8.4.1.3. Retail Pharmacies
      • 8.4.1.4. Online Pharmacies
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Systemic Scleroderma Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 8.5.1.2. GCC Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.3. GCC Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.4. GCC Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.5. South Africa Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 8.5.1.6. South Africa Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.7. South Africa Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.8. South Africa Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.9. Egypt Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 8.5.1.10. Egypt Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.11. Egypt Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.12. Egypt Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.13. Nigeria Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 8.5.1.14. Nigeria Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.15. Nigeria Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.16. Nigeria Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Systemic Scleroderma Treatment Market by Target Organ, Value (US$ Mn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Systemic Scleroderma Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Systemic Scleroderma Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Systemic Scleroderma Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Target Organ vs Route of Administration Heatmap
  • 9.2. Manufacturer vs Indication Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Novartis AG
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. GlaxoSmithKline plc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Sanofi SA
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Lupin Ltd
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Cipla Ltd
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Johnson & Johnson Services Inc.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Bayer Healthcare LLC
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. F. Hoffmann-La Roche Ltd
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Amgen Inc
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. Zydus Lifesciences Ltd
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. Casper Pharma
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Product Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development
    • 9.5.13. Boehringer Ingelheim Pharmaceuticals, Inc.
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Product Portfolio
      • 9.5.13.3. Financial Overview
      • 9.5.13.4. Business Strategies and Development
    • 9.5.14. Organon LLC
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Product Portfolio
      • 9.5.14.3. Financial Overview
      • 9.5.14.4. Business Strategies and Development
    • 9.5.15. Accord Healthcare Inc.
      • 9.5.15.1. Company Overview
      • 9.5.15.2. Product Portfolio
      • 9.5.15.3. Financial Overview
      • 9.5.15.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations